DIVERSA

At DIVERSA we specialize in pharmaceutical technology and #drugdelivery solutions using our lipid nanoemulsions. Today we are starting our participation #bioeuropespring and look forward to connecting with many prospective partners. Let's start the therapeutic revolution. Thanks to Scienseed for this beautiful animation video.

🌟 Happy New Year 2025! 🌟 As we step into a brand-new year, DIVERSA renews its commitment to advancing innovative solutions in healthcare through cutting-edge nanotechnology. 🚀 2025 will be a year of growth, collaboration, and impactful innovation as we continue to push boundaries, harnessing nanotechnology to bring transformative solutions closer to patients and clinicians worldwide. From precision delivery systems to groundbreaking therapeutics, we are dedicated to redefining the future of medicine. We are deeply grateful to our partners, collaborators, and supporters for their unwavering trust and inspiration. Together, we are shaping the #FutureOfHealthcare through innovation and dedication. Let’s make 2025 a year to remember, filled with progress, purpose, and meaningful breakthroughs in healthcare innovation! ✨ Stay connected for exciting updates and achievements ahead! ✨ #HappyNewYear2025 #Nanotechnology #HealthcareInnovation #DIVERSATechnologies #InnovativeSolutions #BusinessDevelopment #FutureOfHealthcare

Explore how innovative material choices are revolutionizing nanotechnology in biomedicine, unlocking new possibilities for drug delivery and diagnostics. 📖 Learn about the key differences between inorganic and organic nanoparticles, and why lipid-based nanoparticles are at the forefront of safer and more effective therapies. From mRNA vaccines to advanced gene therapies, the biocompatibility and biodegradability of LNPs make them an outstanding choice 👉 https://lnkd.in/deC_CfKF. 💡 Don't miss out:  Swipe to see how, at DIVERSA, we design nanoparticle solutions that go beyond innovation, ensuring full compliance with safety and regulatory standards. Our meticulous material selection and alignment with FDA/EMA regulations set us apart from the competition. #Nanotechnology #Biomedicine #DrugDelivery #Nanoparticles #LipidNanoparticles #Innovation #PrecisionMedicine #Safety #Research

DIVERSA Technologies SL, one of the 10 companies selected to join the Incubadora Universidad de Navarra, a prestigious program aimed at accelerating innovative startups in the health and life sciences sectors. Participation in the incubator program offers DIVERSA access to specialized mentoring from clinical experts at the Clínica Universidad de Navarra, as well as a vast network of investors and academic resources provided by the University of Navarra This milestone was officially announced during the Health Startup Forum, held on October 23, 2024, in Madrid. The event brought together startups, investors, clinicians, and experts in innovation and entrepreneurship, providing a platform for emerging companies to showcase their groundbreaking solutions. Additionally, on December 9th, Dr. Maria de la Fuente Freire, CEO/CSO of DIVERSA, traveled to Pamplona to hold her first meeting with Javier Robledo, key member of the University of Navarra's Incubator team, specializing in project management and business development, and Dr. Javier Rodríguez , Co-Director of the Department of Medical Oncology at Clínica Universidad de Navarra, with invaluable expertise in gastrointestinal tumours and access of innovative therapies to clinic. This meeting marked the beginning of an exciting collaboration under this incubator program. Don’t miss the chance to discover more about this project, stay tuned and follow us at https://lnkd.in/gy_xySXz #HealthCareInnovation #StartupSuccess #GastrointestinalCancer #Nanomedicine 📸 Grateful to Incubadora Universidad de Navarra for the second and third photos. Thank you for capturing these unforgettable memories! 🙌

🌟 Nanomedicine in 2024: Key Advances and Future Directions 🌟 2024 has been a groundbreaking year for nanomedicine. Key advancements in mRNA therapies, cancer immunotherapy, and biodegradable nanopharmaceuticals are revolutionizing healthcare as we know it. 💡 Swipe through our carousel for highlights, and visit our blog to dive deeper into how nanotechnology is driving the future of medicine: 👉 [Read the full blog here] https://lnkd.in/dJQa5dnF #Nanomedicine #Nanotechnology #mRNATherapies #CancerImmunotherapy #MedicalInnovation #FutureOfHealthcare #Biotechnology #ScientificBreakthroughs

🚀 We’re Hiring! Here at DIVERSA Technologies, we continue to grow! We are looking for an Experienced Research Scientist to join our team! At DIVERSA we specialize in the formulation and intracellular delivery of therapeutic molecules, offering them new opportunities to develop into the clinic. Molecules that otherwise would not reach their site of action, can now be delivered to the target with their therapeutic properties intact thanks to our patented delivery technology. DIVERSA’s ambition is to prompt the development of innovative therapies for the ultimate benefit of patients, starting a therapeutic revolution. DIVERSA offers an open position as Experienced Research Scientist . This position is a unique opportunity to add value to the growing field of biotechnology and to develop a professional career in a biotech company projected to be a reference in the sector of drug delivery and nanomedicine. We are seeking a highly qualified candidate for a long-term postdoctoral contract. The employee is expected to work on multiple on-going and up-coming R&D projects, with a cross-disciplinary team. The employee must excel in a dynamic, multitasking environment, demonstrating strong teamwork skills while contributing to the efficient operation of the R&D department and laboratory, upholding the high-quality standards established by DIVERSA. 🔑 Key Responsibilities: Lead the design and execution of experiments to optimize nanoformulations for therapeutic applications, drive innovation in nanoparticle characterization and collaborate with cross-functional teams to integrate R&D findings into clinical applications. Oversee laboratory operations, mentor junior researchers, and establish strategic collaborations with academic and industry partners. Contribute to high-impact publications, patents, and the development of scalable nanoparticle production protocols. 🎓 Qualifications: The ideal candidate should hold a PhD in Pharmacy, Biology, Biotechnology, or a related field. Expertise in nanomedicine, pharmaceutical formulation, and gene delivery is essential, with demonstrated experience in in-vitro and in-vivo testing. The candidate should have experience working in collaborative, cross-disciplinary teams and possess in-depth knowledge of laboratory instrumentation, purification techniques, and data analysis. Proficiency in nanoparticle characterization and drug/lipid design principles is required. The candidate must have strong scientific knowledge, a track record of publications, and fluency in English. ✨ Why Join Us? Join DIVERSA for the opportunity to work in an innovative, interdisciplinary research environment, offering a flexible schedule, competitive salary, and excellent conditions for personal and professional growth. 🗓 Deadline to Apply: January 7th, 2025 📩 Send your CV to: info@diversatechnologies.com Subject line: Application for Experienced Research Scientist 📍 Learn more about us: https://lnkd.in/eCdptm8

📢 DIVERSA has been awarded the "Proyectos de Colaboración Público-Privada" (CPP2023-010787) call, funded by the Agencia Estatal de Investigación - Ministry of Science and Innovation of Spain/Ministerio de Ciencia, Innovación y Universidades (MICIU/AEI /10.13039/501100011033), and co-funded by the European Union (FEDER funds). The project entitle INCANTA, from "Innovating Cancer Treatment with Nanoimmunotherapeutics" is aimed to develop mRNA-based therapeutics for the treatment of locally advanced cancer. This project strongly relies on key collaborations with Pedro Berraondo from Cima Universidad de Navarra and Jenifer García Fernández from Health Research Institute of Santiago de Compostela, whose invaluable expertise in cancer immunotherapy and the interaction mechanisms of advanced nanosystems with cancer cells significantly enriches our work. This marks a significant milestone for DIVERSA, highlighting our commitment to driving innovation in the healthcare sector and advancing therapies to address unmet clinical needs. We sincerely thank our collaborators for partnering with us on this important journey!

🎄✨ Season's Greetings from DIVERSA Technologies! ✨🎄   As we wrap up another year of innovation and breakthroughs, we want to thank all our partners, clients, and supporters for being part of our journey. 🚀   This festive season, may your days be as bright as our fluorescent nanoparticles, your challenges as manageable as our optimized formulations, and your New Year as promising as our cutting-edge technology. 🌟🔬 Here’s to a 2025 filled with infinite possibilities and collaborative success.   From all of us at DIVERSA, Happy Holidays and a Prosperous New Year! 🥂 🎉 #Innovation #Science #HolidayWishes #DIVERSATechnologies

Explore how innovative material choices are revolutionizing nanotechnology in biomedicine, unlocking new possibilities for drug delivery and diagnostics. 📖 Learn about the key differences between inorganic and organic nanoparticles, and why lipid-based nanoparticles are at the forefront of safer and more effective therapies. From mRNA vaccines to advanced gene therapies, the biocompatibility and biodegradability of LNPs make them an outstanding choice 👉 https://lnkd.in/deC_CfKF. 💡 Don't miss out:  Swipe to see how, at DIVERSA, we design nanoparticle solutions that go beyond innovation, ensuring full compliance with safety and regulatory standards. Our meticulous material selection and alignment with FDA/EMA regulations set us apart from the competition. #Nanotechnology #Biomedicine #DrugDelivery #Nanoparticles #LipidNanoparticles #Innovation #PrecisionMedicine #Safety #Research

💡 Innovation driving results Peptomyc, one of our valued clients, relied on DIVERSA’s patented nanoparticle technology to encapsulate mRNA for their project. The objective of this experiment was to enable the expression of a protein that effectively reaches its site of action in the nucleus. This represents a key step in their broader efforts to develop innovative therapeutic solutions. The results highlight the superior capabilities of our designed nanoparticles compared to Lipofectamine 🟢 📸. Immunofluorescence images captured by Sandra Martínez Martín reveal efficient mRNA internalization and precise nuclear localization of the expressed proteins (nuclei stained in blue; protein in green). This project was proudly funded by the Activa StartUp 2023 program of the EOI Business School. Together, we are advancing towards a safer, more efficient future in gene therapy delivery! 🚀 #Innovation #Nanomedicine #ClientResults #DIVERSA #ScienceInAction